Concizumab
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia[1][2].
Product Specifications
CAS Number
1312299-39-0
Product Name Alternative
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
UNSPSC
12352203
Target
Factor Xa
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/concizumab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Concizumab]
Molecular Weight
(146.28 kDa)
References & Citations
[1]Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19 (7) :1687-1696. |[2]Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC428009 20 µg
SMC6L1 (SMC6) (NM_001142286) Human Over-expression Lysate
Sign In for Pricing
View Details